Research
Hormonal
Metformin use is associated with a reduced incidence of hepatocellular carcinoma in patients with type 2 diabetes, whereas sulfonylurea or insulin use may increase risk.
If you have type 2 diabetes, talk to your doctor about whether metformin is the right choice for you. Research suggests that metformin may lower your risk of liver cancer compared to other diabetes medications like insulin or sulfonylureas.
GoodSupportsMEDIUM confidence
A meta-analysis including 22,650 cases of HCC in 334,307 patients with T2DM concluded that incidence of HCC was reduced by 50% with metformin use, increased with sulfonylurea or insulin and unchanged with glitazones
Why this rating
Based on a large meta-analysis of observational data.
Source
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Andrea Marengo et al. · Annual Review of Medicine · 2015
DOI 10.1146/annurev-med-090514-013832
narrative_reviewCited 790×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and metabolic syndrome significantly increase the risk of hepatocellular carcinoma (HCC), with risk escalating as BMI increases and being further amplified by the presence of type 2 diabetes.Strong
- Hepatocellular carcinoma can develop in patients with nonalcoholic fatty liver disease (NAFLD) even in the absence of cirrhosis, often presenting with larger tumors and poorer prognosis due to lack of surveillance.Good
- Statin use is associated with a reduced incidence of hepatocellular carcinoma in patients with NAFLD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →